免疫疗法是治疗癌症的强大策略，可用于抑制肿瘤术后复发。为了实现这一目标，使用 CT26 肿瘤细胞和 Pluronic® F-127/明胶的混合物开发了 Cell@水凝胶作为模板所提出的混合物具有溶液到凝胶的功能，反之亦然。 Cell@水凝胶的形态通过扫描电子显微镜和共焦显微镜进行表征。对于光动力免疫疗法，Cell@水凝胶用 Cy7 (Cy7-Cell@水凝胶) 进行功能化，以量化 CT26 肿瘤细胞中的活性氧。进行凝胶电泳和膜完整性测试，以确定 Cy7-Cell@水凝胶在光动力治疗后的效率。该方案提供了一种替代方法，可机械地抑制基于免疫疗法的实体瘤术后复发。版权所有 © 2024。爱思唯尔有限公司

Immunotherapy is a powerful strategy for treating cancer and can be used to inhibit the post-surgical relapse of tumors.To achieve this, a Cell@hydrogel was developed as a template using a mixture of CT26 tumor cells and Pluronic® F-127/gelatin.The proposed mixture has a solution-to-gelation functionality and vice versa. The morphology of the Cell@hydrogel was characterized by scanning electron microscopy and confocal microscopy. For photodynamic immunotherapy, the Cell@hydrogel was functionalized with Cy7 (Cy7-Cell@hydrogel) to quantify reactive oxygen species in CT26 tumor cells. Gel electrophoresis and membrane integrity tests were performed to determine the efficiency of the Cy7-Cell@hydrogel following photodynamic therapy.This protocol provides an alternative approach that mechanistically inhibits the post-surgical relapse of solid tumors based on immunotherapy.Copyright © 2024. Published by Elsevier B.V.